I believe strongly in role models. Dr. J Stuart Wolf, Jr formerly a professor of Urology at the University of Michigan Medial School and now the Associate Chair for Clinical Integration at the University of Texas Dell Medical School at Austin started my interest in both urology and research. Under his tutelage, I graduated from the University of Michigan Medical School with both academic and research distinction. He also introduced me to the late Dr. Richard Williams of the University of Iowa where I did my residency. Dr. Williams was an amazing man, an incredible leader, a brilliant researcher and gifted surgeon whose life ended too soon.
Dr. Williams once told me that not every urologist will become the chairman of a department or win the Nobel prize, but that every urologist has a responsibility to make a contribution to the field. During my time both in medical school and residency I published over two dozen peer-reviewed articles on a wide range of urological topics; I wrote four book chapters on various urological topics and I contributed to almost 40 abstracts presented at various conferences. While it has been many years since I have written a peer-reviewed article, I still review articles for both PLOS-ONE and the Journal of Urology.
Complete List of Peer-Reviewed Articles
1. Rosevear HM, Montgomery JS, Roberts WW, Wolf JS Jr. Characterization and management of postoperative hemorrhage following upper retroperitoneal laparoscopic surgery. J Urol 2006;176:1458-62.
https://www.ncbi.nlm.nih.gov/pubmed/16952660
2. Rosevear H.M., Wald M. Grafting Techniques for Vasectomy Reversal. In: Parekattil S., Agarwal A. (eds) Male Infertility. Springer, New York, NY. 2012
https://www.ncbi.nlm.nih.gov/pubmed/18068437
3. Wenzler DL, Kim SP, Rosevear HM, Faerber GJ, Roberts WW, Wolf JS Jr. Success of ureteral stents for intrinsic ureteral obstruction. J Endourol 2008;22:295-9.
https://www.ncbi.nlm.nih.gov/pubmed/18294036
4. Malhotra R, Tyson DW, Rosevear HM, Brosius FC 3rd. Hypoxia-inducible factor-1alpha is a critical mediator of hypoxia induced apoptosis in cardiac H9c2 and kidney epithelial HK-2 cells. BMC Cardiovasc Disord 2008;8:9.
https://www.ncbi.nlm.nih.gov/pubmed/18447926
5. Rosevear HM, Meier MM, Gallagher BL, Joudi FN. Surgically discovered xanthogranulomatous pyelonephritis invading inferior vena cava with coexisting renal cell carcinoma. TSW Urol 2009;9:5-9.
https://www.ncbi.nlm.nih.gov/pubmed/19151892
6. Rosevear HM, Mishail A, Sheynkin Y, Wald M. Unusual scrotal pathology: an overview. Nat Rev Urol 2009;6:491-500.
https://www.ncbi.nlm.nih.gov/pubmed/19668251
7. Rosevear HM, Lightfoot AJ, O’Donnell MA, Griffith TS. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev 2009;28:345-53.
https://www.ncbi.nlm.nih.gov/pubmed/19967427
8. Rosevear HM, Lightfoot AJ, Griffith TS. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer. Curr Opin Invest Drugs 2010;11:688-98.
https://www.ncbi.nlm.nih.gov/pubmed/20496264
9. Rosevear HM, Lightfoot AJ, Zahs M, Waxman SW, Winfield HN. Lessons learned from a case of calf compartment syndrome following robotically-assisted laparoscopic prostatectomy. J Endourol 2010;24:1597-601.
https://www.ncbi.nlm.nih.gov/pubmed/20629565
10. Bittner JG, Rosevear HM, Lightfoot AJ, Johnson T, Brown JA. Buttressed horizontal mattress suture closure after partial nephrectomy: a novel modification using human cadaveric pericardium. J Endourol Part B VideoUrology 2010, volume 24, number 3.
11. Rosevear HM, Lightfoot AJ. Nepple KG. O’Donnell MA. Safety and efficacy of intravesical bacillus Calmette-Guerin (BCG) plus interferon alpha-2B therapy for non-muscle invasive bladder cancer (NMIBC) patients with prosthetic devices. J Urol 2010;184:1920-4.
https://www.ncbi.nlm.nih.gov/pubmed/20846678
12. Nepple KG, Lightfoot AJ, Rosevear HM, O’Donnell MA, Lamm DL. Multicenter randomized study of BCG with or without interferon and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of non-muscle invasive bladder cancer. J Urol 2010;184:1915-9.
https://www.ncbi.nlm.nih.gov/pubmed/20846688
13. Lightfoot AJ, Rosevear HM, Kreder KJ. Inflatable penile prostheses: an update Curr Opin Urol 2010;20:459-64.
https://www.ncbi.nlm.nih.gov/pubmed/20625296
14. Rosevear HM, Lightfoot AJ, O’Donnell MA. Usefulness of the CUETO scoring model for predicting non-muscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guerin plus interferon-alpha. J Urol 2011; 185: 67-71.
http://www.sciencedirect.com/science/article/pii/S0022534710045246
15. Lightfoot AJ, Rosevear HM, O’Donnell MA. Recognition and treatment of BCG failure in bladder cancer. TSW Urology 2011;11:602–613.
https://www.ncbi.nlm.nih.gov/pubmed/21399857
16. Lightfoot AJ, Rosevear HM, Steers WD, Tracy CR. Current and future need for academic urologists in the United States. J Urol 2011;185:2283-7.
https://www.ncbi.nlm.nih.gov/pubmed/21497844
17. Rosevear HM, Lightfoot AJ, O’Donnell MA, Platz CE, Loening SA, Hawtrey CE. Rubin H. Flocks and colloidal gold treatments for prostate cancer. TSW Urol TheScientificWorldJOURNAL 2011;(11):1560–1567.
https://www.ncbi.nlm.nih.gov/pubmed/22224070
18. Rosevear HM, Lightfoot AJ, Birusingh KK, Maymi JL, O’Donnell MA, National BCG/Interferon Investigator Group. Factors affecting response to BCG plus interferon in patients with urothelial carcinoma in situ (CIS). J Urol 2011;186:817-23.
https://www.ncbi.nlm.nih.gov/pubmed/21788050
19. Rosevear HM, Gellhaus PT, Lightfoot AJ, Kresowik TP, Joudi FN, Tracy CR. The utility of the R.E.N.A.L nephrometry scoring system in the real world: predicting surgeon operative preference and complication risk. BJU Int 2012;109:700-705
https://www.ncbi.nlm.nih.gov/pubmed/21777362
20. Rosevear HM, Lightfoot AJ, Powell CR, Weisleder P, Vidaurre J, Lehman N, Moorthy LN. Index of Suspicion. Case 1: Voiding difficulty in a 10-year-old. Pediatr Rev 2011;32:447-52.
http://pedsinreview.aappublications.org/content/32/10/447
21. Norian LA, Kresowik TP, Rosevear HM, James BR, Rosean TR, Lightfoot AJ, Kucaba TA, Schwarz C, Weydert CJ, Henry MD, Griffith TS. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One. 2012;7(2):e31085. Epub 2012 Feb 1.
https://www.ncbi.nlm.nih.gov/pubmed/22312440
22. Rosevear HM, Krishnamachari, Y, Aziza CA, Mallaproagada SK, Salem AK, Griffith TS, DeYoung B, Wald M. Effect of combined locally delivered growth factors and systemic sildenafil citrate on the number of micro-recanals in a biodegradable conduit for reconstruction of the vas deferens. Urology 2012;79(4): 967. e1-4.
23. Nepple K, Rosevear HM, Stolpen AH, Brown JB, Williams RD. Concordance of preoperative prostate endorectal MRI with subsequent prostatectomy specimen in high-risk prostate cancer patients. Urol Oncol (2011) Jun 10 (epub).
https://www.ncbi.nlm.nih.gov/pubmed/21665495
24. Rosevear HM, Williams H, Collins M, Lightfoot AJ, Coleman T, Brown JA. Utility of 18F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes. Urol Oncol 2012 Sep; 30(5): 723-6.
https://www.ncbi.nlm.nih.gov/pubmed/21396850
25. Lightfoot AJ, Rosevear HM, Nepple K, O’Donnell MA. Role of transurethral biopsy and isolated upper tract cytology following intravesical treatment of high grade non-muscle invasive bladder cancer. Int J Urol 2012 Nov; 19(11) 988-93.
https://www.ncbi.nlm.nih.gov/pubmed/22762480
26. Lightfoot AJ, Breyer BN, Rosevear HM, Erickson BA, Konety BR, O’Donnell MA. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer. Urologic oncology. 2014;32(1):35.e15-35.e19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113080/
27. Berneking, AD. Rosevear, HM. Askeland, EJ, Newton, MR, O’Donnell, MA. Brown, JA. Morbidity and mortality of octogenarians following open radical cystectomy using a standardized reporting system. Can J Urol. 2013 Aug.
https://www.ncbi.nlm.nih.gov/pubmed/23930606
Book Chapters
1. Lightfoot AJ, Rosevear HM, O’Donnell MA. High-risk non-invasive bladder cancer (HG Ta, CIS). In Vogelzang NJ, Scardino PT, Zelefsky MJ, Linehan WM (eds): Comprehensive Textbook of Genitourinary Oncology, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2011.
2. Rosevear HM, Wald M. Grafting techniques for vasectomy reversal. In Parekattil SJ, Agarwal A (eds): Antioxidants in the Medical and Surgical Treatment of Male Infertility. Springer Science and Business, 2012.
3. Lightfoot AJ, Rosevear HM, O’Donnell MA. Conservative management of non-muscle invasive bladder cancer after BCG failure. In Nilsson WE (ed): Bladder Cancer: Etymology, Diagnosis and Treatments. Hauppauge, NY: Nova Science Publishers, 2010.
4. Rosevear HM, Lightfoot AJ, Brown JA, O’Donnell MA. Intravesical therapies for non-muscle invasive bladder cancer. In Essentials and Updates in Urologic Oncology. Hauppauge, NY: Nova Science Publishers, 2012.
Abstracts and Presentations
1. Rosevear HM, Brosius FC. Hif-1alpha critically enhances hypoxia-induced apoptosis. University of Michigan Medical School Student Biomedical Research Poster Presentation, 2004.
2. Rosevear HM, Montgomery JS, Roberts WW, Wolf JS Jr. Characterization and management of postoperative hemorrhage following upper retroperitoneal laparoscopic surgery. 2nd Annual Michigan Urology Research Symposium Poster Presentation, 2006.
3. Kim S, Rosevear HM, Dunn R, Hembroff L, Holmes-Rovner M, Rovner D, Taub D, Fagerlin A, Wei JT. Sociodemographic variation in the use of information among prostate cancer patients. American Urological Association Annual Meeting, 2006.
4. Waxman S, Rosevear HM, Lightfoot AJ, Winfield HN. Complications of laparoscopic renal surgery. North Central Section of the American Urological Association Annual Meeting, 2009.
5. Rosevear HM, Lightfoot AJ, O’Donnell MA. Intravesical bacillus Calmette-Guerin (BCG) and interferon alpha-2b therapy for patients with non-muscle invasive bladder cancer (NMIBC) who have pacemakers or artificial heart valves (AHVS). Society of Urologic Oncology Annual Meeting, 2009.
6. Rosevear HM, Lightfoot AJ, O’Donnell MA. Cancer recurrence disparities among racial and gender groups with non-muscle invasive bladder cancer (NMIBC) after intravesical bacillus Calmette-Guerin (BCG) and interferon alpha-2b therapy. Society of Urologic Oncology Annual Meeting, 2009.
7. Lightfoot AJ, Rosevear HM, O’Donnell MA. Postoperative administration of chemotherapy following transurethral resection of bladder tumor (TURBT) for non-muscle invasive bladder cancer (NMIBC). Society of Urologic Oncology, Annual Meeting, 2009.
8. Waxman S, Lightfoot AJ, Rosevear HM, Winfield HN. Complications of laparoscopic renal surgery. Society of Government Service Urologist’s Annual Meeting, 2010.
9. Rosevear HM, Lightfoot AJ, O’Donnell MA. Intravesical bacillus Calmette-Guerin (BCG) and interferon alpha-2b therapy for patients with non-muscle invasive bladder cancer (NMIBC) who have pacemakers or artificial heart valves (AHVS). American Society of Clinical Oncology Genitourinary Cancer Symposium, 2010.
10. Rosevear HM, Lightfoot AJ, O’Donnell MA. Validation of the CUETO Scoring Model for predicting non-muscle invasive bladder cancer (NMIBC) recurrence in patients treated with intravesical bacillus Calmette-Guerin (BCG). American Society of Clinical Oncology Genitourinary Cancer Symposium, 2010.
11. Lightfoot AJ, Rosevear HM, O’Donnell MA. Formal restaging procedure following treatment of high grade non-muscle invasive bladder cancer (NMIBC). American Society of Clinical Oncology Genitourinary Cancer Symposium, 2010.
12. Lightfoot AJ, Rosevear HM, Steers W, Tracy C. The current state of academic urology. North Central Section of the American Urological Association Annual Meeting, 2010.
13. Lightfoot AJ, Rosevear HM, Nepple KG, O’Donnell MA. Topical treatment of high grade upper tract urothelial carcinoma (UTUC). North Central Section of the American Urological Association Annual Meeting, 2010.
14. Rosevear HM, Lightfoot AJ, O’Donnell MA. Cancer recurrence disparities among racial and gender groups with non-muscle invasive bladder cancer (NMIBC) after intravesical bacillus Calmette-Guerin (BCG) and interferon alpha-2b therapy. North Central Section of the American Urological Association Annual Meeting, 2010.
15. Lightfoot AJ, Rosevear HM, Nepple KG, O’Donnell MA. Novel intravesical immunotherapy. North Central Section of the American Urological Association Annual Meeting, 2010.
16. Lightfoot AJ, Rosevear HM, Nepple KG, O’Donnell MA. Formal restaging procedure following treatment of high grade non-muscle invasive bladder cancer (NMIBC). North Central Section of the American Urological Association Annual Meeting, 2010.
17. Rosevear HM, Lightfoot AJ, O’Donnell MA. Factors affecting response to BCG+interferon alpha-2B in patients with urothelial carcinoma in situ (CIS). North Central Section of the American Urological Association Annual Meeting, 2010
18. Lightfoot AJ, Rosevear HM, Cheng M, Brown JA. Bricker ileal conduit: novel modifications to facilitate ease of construction. North Central Section of the American Urological Association Annual Meeting, 2010.
19. Rosevear HM, Lightfoot AJ, Bittner JG, Johnson T, Brown JA. Buttressed horizontal mattress suture closure after partial nephrectomy: a novel modification using human cadaveric pericardium. North Central Section of the American Urological Association Annual Meeting, 2010.
20. Gellhaus PT, Rosevear HM, Lightfoot AJ, Kresowik TK, Joudi F, Tracy CR. The R.E.N.A.L. nephrometry scoring system predicts surgeon operative preference for renal masses. World Congress of Endourology and SWL Annual Meeting, 2010.
21. Norian LA, Kresowik TK, Kucaba TA, Lightfoot AJ, Rosevear HM, Schwarz C, Griffith TS. Combinatorial TNF-related apoptosis-inducing ligand (TRAIL) plus CpG immunotherapy shows efficacy against metastatic renal cell carcinoma in mice. Immunology Annual Meeting, 2010.
22. Berneking AD, Rosevear HM, Brown JA, O’Donnell MA. Comparative outcomes in octogenarians undergoing radical cystectomy. Medical Student Symposium, University of Iowa, 2010.
23. Rosevear HM, Lightfoot AJ, O’Donnell MA. Impact of time on the ability of UroVysion FISH analysis to predict recurrence of urothelial cell carcinoma. Society of Urologic Oncology Annual Meeting, 2010.
24. Gellhaus PT, Rosevear HM, Lightfoot AJ, Kresowik TK, Joudi F, Tracy CR. The R.E.N.A.L. nephrometry scoring system predicts surgeon operative preference for renal masses. Society of Urologic Oncology Annual Meeting, 2010.
25. Lightfoot AJ, Nepple KG, Rosevear HM, O’Donnell MA. Topical treatment of upper tract urothelial carcinoma in-situ. Society of Urologic Oncology Annual Meeting, 2010.
26. Rosevear HM, Lightfoot AJ, O’Donnell MA. Ability of UroVysion FISH analysis to select patients with low or intermediate risk non-muscle invasive bladder cancer for decreased surveillance. Society of Urologic Oncology Annual Meeting, 2010.
27. Rosevear HM, Lightfoot AJ, O’Donnell MA. Utility of quantitative fluorescent in-situ hybridization (FISH) to predict non-muscle invasive bladder cancer Recurrence. Society of Urologic Oncology Annual Meeting, 2010.
28. Berneking AD, Rosevear HM, Brown JA, O’Donnell MA. Comparative outcomes in octogenarians undergoing radical cystectomy. Society of Urologic Oncology Annual Meeting, 2010.
29. Lightfoot AJ, Carpenter BT, Rosevear HM, O’Donnell MA. Extravesical non-muscle invasive involvement of urothelial cancer. Society of Urologic Oncology Annual Meeting, 2010.
30. Rosevear HM, Lightfoot AJ, O’Donnell MA. Ability of UroVysion FISH analysis to select patients with low or intermediate risk non-muscle invasive bladder cancer for decreased surveillance. American Society of Clinical Oncology Genitourinary Cancer Symposium, 2011.
31. Rosevear HM, Lightfoot AJ, O’Donnell MA. Utility of quantitative fluorescent in-situ hybridization (FISH) to predict non-muscle invasive bladder cancer Recurrence. American Society of Clinical Oncology Genitourinary Cancer Symposium, 2011.
32. Rosevear HM, Krishnamachari, Y, Aziza CA, Mallaprogada SK, Salem AK, Griffith TS, DeYoung B, Wald M. Wald AUA rat project. Effect of combined locally delivered growth factors and systemic sildenafil citrate on the number of micro-recanals in a biodegradable conduit for reconstruction of the vas deferens. American Urological Association Annual Meeting, 2011
33. Feifer A, Taylor J, Shouery M, Savage C, Steinberg G, Stadler W, DeCastro J, Lerner S, Godoy G, Lotan Y, Feldman A, Psutka S, Kassouf W, Yafi F, Zlotta A, Black P, Schoenberg M, Grubb III R, O’Donnell M, Rosevear HM, Stephenson A, Patel A, Lee C, Weizer A, Bajorin D, Milowsky M, Dalbagni G, Ethan Basch E, Bochner B. Multi-institutional quality of care initiative for non-metastatic muscle-invasive transitional cell carcinoma of the bladder: Phase 1. American Urological Association Annual Meeting, 2011.
34. Rosevear HM, Lightfoot AJ, Griffith TS, Dahmoush L, O’Donnell MA. Correlation of TRAIL receptor expression and clinical outcomes of patients with non-muscle invasive bladder cancer (NMIBC) treated with BCG. North Central Section of the American Urological Association Annual Meeting, 2011.
35. Rosevear HM, Lightfoot AJ. Powell, CR. “Not if Done Correctly” Urethral stricture in a 10-year-old boy associated with bull riding. North Central Section of the American Urological Association Annual Meeting, 2011.
36. Lightfoot AJ, Carpenter B, Rosevear HM, O’Donnell MA. Extravesical non-muscle invasive involvement of urothelial cancer. North Central Section of the American Urological Association Annual Meeting, 2011.
37. Lightfoot AJ, Breyer BN, Rosevear HM, Konety BP, O’Donnell MA. Multi-institutional review of sequential intravesical gemcitabine and mitomycin C chemotherapy in patients with non-muscle invasive bladder cancer (NMIBC). North Central Section of the American Urological Association Annual Meeting, 2011.
38. Lightfoot AJ, Breyer BN, Rosevear HM, Konety BP, O’Donnell MA. Multi-institutional review of sequential intravesical gemcitabine and mitomycin C chemotherapy in patients with non-muscle invasive bladder cancer (NMIBC). American Society of Clinical Oncology Genitourinary Cancer Symposium, 2012.
39. Berneking AD, Rosevear HM, Askeland EJ, Newton MR, O’Donnell MA, Brown JA. Morbidity and mortality of octogenarians following open radical cystectomy using a standardized reporting system. Society of Government Services Urologists, 60th Annual Kimbrough Seminar, Honolulu, HI, January 20-25, 2013.